Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
May 20, 2019--ARIKAYCE Plus Guideline-Based Therapy (GBT) Associated with Significantly Higher Rates of Sustained Culture Conversion on Therapy and Durable Culture Conversion Three Months Post-Treatment Compared with GBT Alone--
-
May 7, 2019-- ARIKAYCE® (amikacin liposome inhalation suspension) U.S. Net Product Sales $21.0 Million for the First Quarter of 2019 --
-
Apr 9, 2019--Patent is 10th Issued in the U.S. for ARIKAYCE and Second Extending Patent Protection into 2035--
-
Apr 8, 2019--ARIKAYCE Preliminary U.S. Net Product Sales Approximately $21.0 Million for the First Quarter of 2019--
-
Apr 1, 2019--Sustainability and Durability Data from Phase 3 CONVERT Study of ARIKAYCE to be Presented in Late-Breaking Oral Session--
-
Mar 27, 2019
-
Feb 22, 2019--ARIKAYCE® (amikacin liposome inhalation suspension) U.S. Net Product Sales of $9.2 Million for the Fourth Quarter and Full Year 2018--
-
Jan 4, 2019-ARIKAYCE Preliminary Unaudited U.S. Net Product Sales Approximately $9.2 Million for the Fourth Quarter of 2018-
-
Nov 8, 2018—Seasoned Pharmaceutical Executive Elizabeth McKee Anderson Appointed as New Director—
-
Nov 6, 2018
-
Oct 30, 2018—Quarter Highlighted by U.S. FDA Approval of ARIKAYCE® (amikacin liposome inhalation suspension), Followed by Immediate Launch—
-
Oct 4, 2018New Patent Adds 7 ½ Years of Market Exclusivity in Japan
-
Oct 1, 2018
-
Sep 28, 2018Commercial availability expected in early Q4 2018
-
Sep 17, 2018As previously reported, study met primary endpoint of culture conversion (p<0.0001)
-
Aug 27, 2018Advisory committee supports surrogate endpoint of sputum culture conversion
-
Aug 2, 2018PDUFA (Prescription Drug User Fee Act) Action Date for ALIS (Amikacin Liposome Inhalation Suspension) Set for September 28, 2018
-
Jun 15, 2018Meeting planned for August 7, 2018
-
Jun 7, 2018
-
May 22, 2018Data support the benefit of treating patients with a combination of ALIS (Amikacin Liposome Inhalation Suspension) and guideline-based therapy (GBT) for the treatment of nontuberculous mycobacterial (NTM) lung disease caused by Mycobacterium avium complex (MAC)
-
May 17, 2018
-
May 16, 2018PDUFA Action Date Set for September 28, 2018
-
May 2, 2018Submitted NDA to FDA for Amikacin Liposome Inhalation Suspension (ALIS) in NTM lung disease caused by MAC; anticipates priority review
-
Mar 29, 2018ALIS previously designated as an orphan drug, breakthrough therapy and Qualified Infectious Disease Product (QIDP)
-
Feb 23, 2018On track to file NDA before the end of March and anticipate a priority review
-
Jan 26, 2018
-
Jan 3, 2018Interim results from INS-312 show that 28% of patients who previously received 6 months of guideline based therapy (GBT) alone achieved culture conversion following addition of ALIS to therapy, consistent with data from the INS-212 study
-
Nov 8, 2017
-
Nov 2, 2017During the third quarter, the Company announced positive top-line results from its Phase 3 CONVERT Study of ALIS (amikacin liposome inhalation suspension) in patients with NTM lung disease caused by MAC, a rare, progressive, destructive lung infection
-
Sep 11, 2017
-
Sep 5, 2017Study met primary endpoint of culture conversion (p < 0.0001)
-
Aug 3, 2017On Track to Report Top-Line Results from Phase 3 CONVERT Study in September plus or minus one month
-
May 15, 2017Paolo Tombesi named as Chief Financial Officer
-
May 3, 2017Advancing Toward Top-Line Results from CONVERT Study in 2H 2017
-
Feb 23, 2017On Track to Report Top-Line Results from CONVERT Study in 2H 2017
-
Nov 3, 2016Enrollment objective achieved in phase 3 CONVERT study
-
Oct 18, 2016Data in American Journal of Respiratory and Critical Care Medicine demonstrate ARIKAYCE's potential to achieve early and sustained negative sputum cultures
-
Feb 25, 2016